Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Immunology

• Publication date

  2018-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4049/jimmunol.1701271PMID 29507120
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 Responses In Vitro Independent of FcαRI and DC-SIGN

  2017cited by this paper
• Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin.

  2017cited by this paper
• IVIG-mediated effector functions in autoimmune and inflammatory diseases

  2017cited by this paper
• Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy

  2017cited by this paper
• The European Hematology Association Roadmap for European Hematology Research: a consensus document.

  2016cited by this paper
• Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.

  2016cited by this paper
• Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

  2016influential reference
• Tackling Difficult Staphylococcus aureus Infections: Antibodies Show the Way.

  2016cited by this paper
• Th17‐ and Treg‐related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease

  2015cited by this paper
• Molecular and immunological biomarkers to predict IVIg response.

  2015cited by this paper
• Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs

  2015cited by this paper
• Intravenous immunoglobulin in neurology—mode of action and clinical efficacy

  2015cited by this paper
• Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

  2015cited by this paper
• Reversal of Arthritis by Human Monomeric IgA Through the Receptor‐Mediated SH2 Domain–Containing Phosphatase 1 Inhibitory Pathway

  2015cited by this paper
• Intravenous immunoglobulin as clinical immune-modulating therapy

  2015cited by this paper
• Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells.

  2014cited by this paper
• Manufacture of Immunoglobulin Products for Patients with Primary Antibody Deficiencies – The Effect of Processing Conditions on Product Safety and Efficacy

  2014cited by this paper
• Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation

  2014cited by this paper
• European consensus proposal for immunoglobulin therapies

  2014cited by this paper
• IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist

  2014cited by this paper
• Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells.

  2014cited by this paper
• Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.

  2013cited by this paper
• Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

  2013cited by this paper
• Intravenous Gammaglobulin Inhibits Encephalitogenic Potential of Pathogenic T Cells and Interferes with their Trafficking to the Central Nervous System, Implicating Sphingosine-1 Phosphate Receptor 1–Mammalian Target of Rapamycin Axis

  2013cited by this paper
• Lack of CD4+CD25+FOXP3+ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease

  2013cited by this paper
• Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk

  2013cited by this paper
• Patients treated with high‐dose intravenous immunoglobulin show selective activation of regulatory T cells

  2013cited by this paper
• Tregitope update: mechanism of action parallels IVIg.

  2013cited by this paper
• Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease

  2012cited by this paper
• Intravenous immunoglobulin for myasthenia gravis.

  2012cited by this paper
• Intravenous immunoglobulin for Guillain-Barré syndrome.

  2012cited by this paper
• Intravenous immune globulin in autoimmune and inflammatory diseases.

  2012cited by this paper
• Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.

  2012cited by this paper
• Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.

  2012cited by this paper
• Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin.

  2011cited by this paper
• Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

  2011cited by this paper
• Comparison of different IVIg preparations on IL-17 production by human Th17 cells.

  2011cited by this paper
• Comparison of IVIg and PLEX in patients with myasthenia gravis

  2011cited by this paper
• Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells

  2010cited by this paper
• Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg).

  2010cited by this paper
• Intravenous Immunoglobulin Therapy in Autoimmune Mucocutaneous Blistering Diseases

  2010cited by this paper
• The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials

  2010cited by this paper
• L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.

  2010cited by this paper
• Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

  2009cited by this paper
• A randomized double-blind trial of intravenous immunoglobulin for pemphigus.

  2009cited by this paper
• Intravenous immunoglobulin therapy for autoimmune diseases

  2009cited by this paper
• Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).

  2008cited by this paper
• Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

  2008cited by this paper
• Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations

  2008cited by this paper
• Shortage of human intravenous immunoglobulin—reasons and possible solutions

  2008cited by this paper
• Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

  2008cited by this paper
• The antiinflammatory activity of IgG: the intravenous IgG paradox

  2007cited by this paper
• A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

  2007cited by this paper
• Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function

  2007cited by this paper
• In search of a cure.

  2007cited by this paper
• Shortage of human intravenous immunoglobulin—reasons and possible solutions

  2007cited by this paper
• Intravenous immunoglobulin for Guillain-Barré syndrome.

  2006cited by this paper
• Purification of intravenous immunoglobulin G from human plasma – aspects of yield and virus safety

  2006cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Immunoglobulin promotes the diversity and the function of T cells

  2006cited by this paper
• The Product: All Intravenous Immunoglobulins Are Not Equivalent

  2005cited by this paper
• Intravenous immunoglobulin for multifocal motor neuropathy.

  2005cited by this paper
• Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

  2004cited by this paper
• B Cell-Dependent TCR Diversification1

  2004cited by this paper
• Intravenous immunoglobulin and the kidney--a two-edged sword.

  2004cited by this paper
• Removal of small non‐enveloped viruses by nanofiltration

  2004cited by this paper
• Intravenous immunoglobulin for myasthenia gravis.

  2003cited by this paper
• Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process

  2003cited by this paper
• Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.

  2003cited by this paper
• Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin.

  2003cited by this paper
• Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG.

  2003cited by this paper
• Proline induces oxidative stress in cerebral cortex of rats

  2003cited by this paper
• Properties of a new intravenous immunoglobulin (IGIV‐C, 10%) produced by virus inactivation with caprylate and column chromatography

  2003cited by this paper
• Red cell agglutination: the first description by creite (1869) and further observations made by landois (1875) and landsteiner (1901)

  2002cited by this paper
• Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg)

  2002cited by this paper
• Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin.

  1999cited by this paper
• Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.

  1998influential reference
• The Noble Chronicles

  1998influential reference
• Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

  1998cited by this paper
• Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease.

  1997cited by this paper
• A metabolic basis for dominance and recessivity.

  1996cited by this paper
• Modulation of complement‐mediated immune damage by intravenous immune globulin

  1996cited by this paper
• Inactivation and removal of blood‐borne viruses

  1995cited by this paper
• A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

  1993cited by this paper
• Intravenous immunoglobulin for multifocal motor neuropathy.

  1992cited by this paper
• Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion.

  1991cited by this paper
• Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood.

  1985cited by this paper
• Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

  1984cited by this paper
• Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin.

  1984cited by this paper
• Non-A, non-B hepatitis from intravenous immunoglobulin.

  1983cited by this paper
• Non-A, non-B hepatitis from intravenous immunoglobulin.

  1983cited by this paper
• High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

  1981cited by this paper
• Letter: Splenectomy and lymphomas.

  1975cited by this paper
• Letter: Mentally subnormal children and their families.

  1973cited by this paper
• Hypogammaglobulinaemia in the United Kingdom. Summary report of a Medical Research Council working-party.

  1969cited by this paper
• Reaction of β-propiolactone with amino acids and its specificity for methionine

  1968cited by this paper
• Reaction of beta-propiolactone with amino acids and its specificity for methionine.

  1968cited by this paper
• The preparation of plasmin treated immune serum globulin for intravenous use.

  1967influential reference
• PATHOGENIC FACTORS IN VASCULAR LESIONS OF EXPERIMENTAL SERUM SICKNESS

  1965cited by this paper
• The precipitation of plasma proteins by short-chain fatty acids.

  1960cited by this paper

• State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens

  2025cites this paper
• COVID-19-associated Autoimmune and Inflammatory Diseases: Molecular Mechanisms and the Role of IVIG Therapy

  2025cites this paper
• Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases

  2025cites this paper
• Charting a course for global progress in PIDs by 2030 — proceedings from the IPOPI global multi-stakeholders’ summit (September 2023)

  2024cites this paper
• Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy

  2023cites this paper
• Evidence for spontaneous regulation of the humoral IgM anti‐GM1 autoimmune response by IgG antibodies in multifocal motor neuropathy patients

  2023cites this paper
• Practise of Immunoglobulin Replacement Therapy in Primary and Secondary Immunodeficiencies: A Single Centre Experience from Malaysia

  2023cites this paper
• Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease

  2022cites this paper
• Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation

  2022cites this paper
• Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 – A theoretical perspective

  2021cites this paper
• Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome

  2021cites this paper
• COVID-19: cross-immunity of viral epitopes may influence severity of infection and immune response

  2021cites this paper
• Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases

  2021cites this paper
• Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases

  2021influential citation
• The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease

  2021cites this paper
• Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches

  2021cites this paper
• Noncanonical Functions of Antibodies.

  2020cites this paper
• APPLICATION OF DESENSITIZATION USING IVIG FOR DONOR SPECIFIC ANTIBODY POSITIVE KIDNEY RECIPIENT. CURRENT SITUATION AND PROBLEMS

  2020cites this paper
• Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer's disease.

  2020cites this paper
• Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review

  2020cites this paper
• Human immunology and immunotherapy: main achievements and challenges

  2020cites this paper
• Passive immunization

  2020cites this paper
• Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils

  2020cites this paper
• Nanocellulose-Based Nanoporous Filter Paper for Virus Removal Filtration of Human Intravenous Immunoglobulin

  2019cites this paper
• Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages

  2019cites this paper
• Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis

  2019cites this paper
• Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection

  2018cites this paper